Lupin Manufacturing Solutions: Empagliflozin API gets CADIFA approval from ANVISA, Brazil
Lupin Manufacturing Solutions has announced that Empagliflozin API, manufactured at its Vizag facility, has received CADIFA approval from ANVISA, Brazil.
Empagliflozin is a proven SGLT-2 inhibitor used in type-2 diabetes care, helping patients control blood sugar and reduce long term complications.
"This approval marks more than a regulatory success; it is a stride toward expanding access to high-quality, effective diabetes therapies worldwide. Backed by scientific rigor, GMP-compliant manufacturing, and a commitment to regulatory excellence, our Empagliflozin API strengthens the fight against type 2 diabetes. Because when it comes to global health, science knows no boundaries," the company stated in a LinkedIn Post.
Lupin Manufacturing Solutions (LMS) is a wholly owned subsidiary of Lupin. The company specializes in manufacturing and supplying high-quality, cost-effective Active Pharmaceutical Ingredients (APIs).
Read also: Lupin wins USFDA nod for Risperidone for extended-release injectable suspension for schizophrenia
Next Story